Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16000934 | 1.00 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL13174451 | 0.80 | TSHR (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL23127960 | 0.78 | CHRNB2 (0.35) | TSHR | |
| SCHEMBL22603218 | 0.78 | CHRNB2 (0.35) | TSHR | |
| SCHEMBL21160229 | 0.78 | ALDH1A1 (0.54) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL9816822 | 0.76 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL16532709 | 0.76 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL16532707 | 0.76 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL9816818 | 0.76 | TSHR (0.50) | TSHRALDH1A1GAACA12CA1 | |
| SCHEMBL16532708 | 0.75 | TSHR (0.54) | TSHRALDH1A1GAACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258967-A1 | PI3 KINASE INHIBITORS AND USES THEREOF | PIK3CA, PIK3CB, PIK3C2B | TSHR 4020/4885ALDH1A1 4394/4885GAA 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.